Happy New Year STOCKHOLDERS –
January 1, 2020 – “Hard-working Americans don’t deserve to pay such high prices for the drugs they need. We are fighting DAILY to make sure this HAPPENS,” he tweeted in November. Many drugmakers had pledged to keep their US list price increases below 10 percent a year, under pressure from politicians and patients. Bristol-Myers raised the price on 10 drugs on Wednesday, including 1.5 percent hikes on cancer immunotherapies Opdivo and Yervoy and a 6 percent increase on its blood thinner Eliquis, all of which bring in billions of dollars in revenue annually. The company also raised the price on Celgene’s flagship multiple myeloma drug, Revlimid, by 6 percent.